Skip to main content

Market Overview

CytoSorbents, Progenity Receive Funding For Product Development

Share:
CytoSorbents, Progenity Receive Funding For Product Development

The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) contract of $1.5 million over 28 months.

  • The funding will be used to advance the development of the K+ontrol platform to treat severe hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.
  • Price Action: CTSO shares are up 0.63% at $7.96 during the market trading session on the last check Tuesday.

Progenity Inc (NASDAQ: PROG) has received funding from the Crohn's & Colitis Foundation's IBD Ventures program to further develop its oral Drug Delivery System to deliver targeted therapeutics for inflammatory bowel disease.

  • Progenity's lead candidates include PGN-001, a high-concentration formulation of adalimumab, and PGN-600, a high concentration, solubilized formulation of tofacitinib.
  • Price Action: PROG shares are trading 5.7% higher at $2.49 during the market trading session on the last check Tuesday.
 

Related Articles (CTSO + PROG)

View Comments and Join the Discussion!

Posted-In: Biotech Government News Penny Stocks Health Care Financing Small Cap FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com